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CD133low phenotype and reduces the
CD133-related invasiveness
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Silvano Capitani1† and Valeria Bertagnolo1*†Abstract
Background: Beyond its possible correlation with stemness of tumor cells, CD133/prominin1 is considered an
important marker in breast cancer, since it correlates with tumor size, metastasis and clinical stage of triple-negative
breast cancers (TNBC), to date the highest risk breast neoplasia.
Methods: To study the correlation between the levels of CD133 expression and the biology of breast-derived cells,
CD133low and CD133high cell subpopulations isolated from triple negative MDA-MB-231 cells were compared in
terms of malignant properties and protein expression.
Results: High expression of CD133 characterizes cells with larger adhesion area, lower proliferation rate and
reduced migration speed, indicative of a less undifferentiated phenotype. Conversely, when compared with
CD133low cells, CD133high cells show higher invasive capability and increased expression of proteins involved in
metastasis and drug-resistance of breast tumors. Among the signalling proteins examined, PLC-β2 expression
inversely correlates with the levels of CD133 and has a role in inducing the CD133high cells to CD133low cells
conversion, suggesting that, in TNBC cells, the de-regulation of this PLC isoform is responsible of the switch from
an early to a mature tumoral phenotype also by reducing the expression of CD133.
Conclusions: Since CD133 plays a role in determining the invasiveness of CD133high cells, it may constitute an
attractive target to reduce the metastatic potential of TNBC. In addition, our data showing that the forced
up-regulation of PLC-β2 counteracts the invasiveness of CD133-positive MDA-MB-231 cells might contribute to
identify unexplored key steps responsible for the TNBC high malignancy, to be considered for potential therapeutic
strategies.
Keywords: Breast cancer, Phospholipase C-β2 (PLC-β2), CD133, Tumor progressionIntroduction
Breast cancer represents a heterogeneous group of tumors
with different morphology, biology and treatment approach
[1]. Triple-negative breast cancers (TNBC), as defined on
the basis of immunohistochemistry and for typically being
negative for estrogen receptor (ER), progesterone receptor* Correspondence: bgv@unife.it
†Equal contributors
1Signal Transduction Unit, Section of Anatomy and Histology, Department of
Morphology, Surgery and Experimental Medicine, University of Ferrara,
Via Fossato di Mortara 70, 44121 Ferrara, Italy
Full list of author information is available at the end of the article
© 2013 Brugnoli et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or(PR) and HER2, represent approximately 20% of all breast
tumors and have a considerable clinical relevance as they
primarily affect young women, appear resistant to con-
ventional chemotherapy regimens, have a particularly poor
prognosis and a significantly worse clinical outcome than
other tumor types [2]. In the management of patients with
TNBC, a promising role seems to be played by the ob-
served relationship between the positivity to the glycosyl-
ated trans-membrane protein CD133 and shorter disease
free and overall survival, suggesting that CD133 expression
may be of help in more accurately predicting the aggressivel Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Figure 1 (See legend on next page.)
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Figure 1 CD133 expression in MDA-MB-231 cells. (A) CD133 surface expression evaluated in MDA-MB-231 cells by means of flow cytometry after
staining with CD133/2 (293C3) and CD133/1 (AC133) phycoerythrin conjugated antibodies and with a hybridoma supernatant (clone 7). The expression
of each antigen is represented on a frequency distribution histogram (count vs. PE signal). The open histograms, outlined by coloured lines, represent
positive staining for CD133 and gray filled histogram shows negative control stained with matched isotype antibody. (B) The surface expression of
CD133, measured with the indicated antibodies, is presented on a biparametric dot plot. The quadrants are gated to separate positive populations. The
percentage of cells expressing high levels of CD133 is indicated at the upper right of each panel, together with their mean fluorescence intensity (MFI).
(C) Western blot analysis with the anti-CD133 antibody on CD133 immunoprecipitated from MDA-MB-231 cells transfected with non-silencing RNAs
(Ctrl siRNAs) or with siRNAs specific for CD133 (CD133 siRNAs). Lysates from the same cells were analyzed for β-tubulin content, as internal control of
processed proteins. (D) Cytofluorimetrical analysis of CD133 expression performed in MDA-MB-231 cells transfected with non-silencing RNAs (Ctrl
siRNAs) or with siRNAs specific for CD133 (CD133 siRNAs). The open histograms, outlined by coloured lines, represent positive staining for CD133 and
gray filled histograms show negative controls stained with matched isotype antibody. (E) CD133 surface expression measured with PE-conjugated
293C3 antibody in MDA-MB-231 cells cultured in the presence of Tunicamycin for 24 hours and shown as dot plots in which the percentage of positive
cells and their mean fluorescence intensity (MFI) are indicated at the upper right. The data are representative of three separate experiments.
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studies suggest that CD133-positivity identifies cancer stem
cells [4] yet the ability of CD133 to reliably identify breast
tumor progenitors is controversial, also due to the use of
different antibodies recognizing CD133 splice variants with
epitopes of different glycosylation status [5]. A strong cor-
relation between CD133 expression and aggressive cellular
behavior, including resistance to chemotherapy and radio-
therapy, was also observed in hepatocellular carcinoma [6],
colon cancers [7] and malignant gliomas [8,9], indicating
that, regardless its role as a marker of stemness of tumor
cells, CD133 may constitute a prognosticator for a number
of different neoplasia.
A functional role of CD133 in tumors is suggested by the
evidence that in vitro targeting of CD133 with a specific
binding peptide reduced colon and breast tumor cell motil-
ity [10] and in vivo down-regulation of CD133 severely im-
paired the capacity of melanoma cells to metastasize [11].
Successful immunotoxin targeting of CD133 in hepatocel-
lular and gastric cancer xenografts has also been reported
[6], suggesting that CD133 may be an important cancer
therapeutic target. On the contrary, even though recent
in vitro data on TNBC correlate CD133 with the inhibitor
of cell cycle progression Geminin [12], at present there is
no evidence that associates CD133 to intracellular proteins
involved in signalling events promoting breast tumor ma-
lignancy and very little is known about the regulation of its
expression in breast tumor cells [13]. A number of sig-
nalling molecules are deregulated in breast neoplasias, in-
cluding specific isoforms of phosphoinositide-dependent
phospholipase C (PLC) that resulted variously involved in
proliferation, migration and invasiveness of tumor cells
[14-17]. We have demonstrated that PLC-β2 expression
strongly correlates with a poor prognosis of patients with
breast tumors [18] and that, in breast tumor-derived cells
with a triple negative phenotype, this PLC isozyme pro-
motes migration and is necessary to sustain invasion cap-
ability [16].
Aim of this work was to elucidate whether CD133 has a
role in determining the malignancy-related properties ofTNBC-derived cells. The relationship of CD133 expres-
sion with proteins known to be de-regulated in breast neo-
plasias, particularly with PLC-β2, was also investigated.
Results
High expression of CD133 characterizes cells with high
invasion capability
MDA-MB-231 cells were subjected to cytofluorimetrical
analysis with two commercially available antibodies directed
against two different CD133 glycosylated epitopes (293C3
and AC133), and an anti-human CD133 monoclonal anti-
body able to specifically recognize an unmodified CD133
extracellular domain (clone 7). Immunophenotyping with
the three antibodies showed similar results indicating that
the entire cell population expresses low levels of CD133
(Figure 1A) and that a small subset of cells (about 2-3%)
express CD133 at much higher levels (Figure 1B). The
specificity of all the used anti-CD133/antibodies was con-
firmed by silencing CD133 expression with specific siRNAs
(Figure 1C, D). The use of Tunicamycin allowed to confirm
that the glycosylation levels of CD133 do not affect the cap-
ability of antibodies to identify expressing cells but may in-
fluence, as expected, the fluorescence intensity, indicative
of the accessibility of the antibody to its specific target epi-
topes (Figure 1E, Additional file 1: Figure S1).
Positive immunomagnetic separation of MDA-MB-
231 cells with the AC133 antibody generated two sub-
populations with significantly different expression levels of
CD133. In particular, a CD133low cell population corre-
sponded to about 93% of cells and a CD133high subpopula-
tion, that included the cells with the greatest expression of
CD133, accounted for about 7% of cells (Figure 2A). The
analysis of intracellular CD133 confirmed the significant
difference of CD133 expression shown by the two sub-
populations (Figure 2B). In addition, the use of Tunicamycin
excluded the possibility that the difference in fluorescence
intensity displayed by the two subpopulations depended
on variable glycosylation levels of CD133, as shown by the
overlapping of the cytometric profiles in the presence or
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Figure 2 CD133-related phenotype of MDA-MB-231 cells. (A) CD133low and CD133high cells, obtained from MDA-MB-231 cells by positive
magnetic separation with CD133/1 Micro Beads, were subjected to the cytofluorimetrical evaluation of CD133 expression with PE-conjugated 293C3
antibody, according to the manufacturer instructions. The data are presented on a biparametric dot plot, in which the mean fluorescence intensity
(MFI) of the entire population is indicated. (B) Intracellular CD133 amount in CD133low and CD133high cells measured with PE-conjugated 293C3
antibody. The MFI of the entire populations were presented as column bar ± SD. The asterisk denotes statistical difference (P < 0.05). (C) CD133 surface
expression measured by flow cytometry after staining with PE-conjugated 293C3 antibody of CD133low and CD133high cells cultured in the presence of
2.5 μg/ml Tunicamycin for 24 hours. The open histograms, outlined by coloured lines, represent positive staining for CD133 and gray filled histogram
shows negative control stained with matched isotype antibody. (D) Adhesion area of CD133low and CD133high cells measured with the ImageJ
software. The data are the mean of 3 separate experiments ± SD. The asterisk indicates statistically significant difference (P < 0.05). (E) Dynamic
monitoring of proliferation, migration and invasiveness through Matrigel using xCELLigence system for the indicated times of CD133low and CD133high
cells. Error bars indicate ± SD. The data are representative of three separate experiments.
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standard culture conditions, showing a stable difference in
CD133 expression levels up to at least 2 passages in
monolayer culture (72 hours).
After 24 hours from separation, CD133low and CD133high
cells were evaluated for morphology and subjected to
impedance-based xCELLigence Real-Time Cell analysis.
Compared to CD133low cells, CD133high cells showed lar-
ger adhesion area (Figure 2D) and lower proliferation rate
and motility (Figure 2E), suggestive of a less undifferenti-
ated tumoral phenotype. On the contrary, invasiveness
measured through Matrigel-coated membranes resulted
significantly higher for CD133high cells (Figure 2E).High CD133 levels correlate with a peculiar protein
expression pattern
To search for specific protein signatures associated to the
two cell subsets identified by CD133 quantitative immuno-
phenotyping, CD133low and CD133high cells were subjected
to proteomic analysis by performing two dimensional elec-
trophoresis followed by mass spectrometry.
By using the PDQuest software, after removal of satu-
rated and poorly reproducible zones, about 380–420 spots
per gel were compared to select proteins whose amount
showed a significant degree of variability between the two
subpopulations expressing different CD133 levels. Three
different proteic maps were analyzed and 27 spots for
each of the two subpopulations were selected for mass
spectrometry analysis. They included 3 proteins whose ex-
pression appeared constant in all samples and 24 spotsTable 1 Proteins differentially expressed in CD133low and CD
two-dimensional electrophoresis combined with mass spectro
Gene symbol Protein name
TPM4 Tropomyosin alpha-4 chain (Tm4)
YWHAE 14-3-3 protein epsilon (14-3-3 ε)
SFN 14-3-3 protein sigma (14-3-3 σ)
YWHAB 14-3-3 protein beta/alpha (14-3-3 β/α)
TCP1 T-complexprotein 1 subunit alpha (TCP-1-α)
SERPINB1 Leukocyteelastaseinhibitor (LEI)
SAHH Adenosylhomocysteinase (AdoHcyase)
EIF2S1 Eukaryotic translation initiation factor 2 subunit 1(eIF-2A)
PPP2CB Ser/threo-protein phosphatase 2A cat. sub. betaisof.(PP2A-β)
EIF3S2 Eukaryotic translation initiation factor 3 subunit 2 (eIF3β)
DDAH1 NG-dimethylargininedimethylaminohydrolase 1 (DDAH-1)
PPA1 Inorganic pyrophosphatase (PPase)
ANXA3 Annexin A3
CAPZB F-actin capping protein subunit beta (CapZβ)
PSME3 Proteasome activator complex subunit 3 (PA28γ)that significantly changed (more than two-fold) their in-
tensity. After analysis performed with the dedicated soft-
ware and searching against the UniProtKB-SwissProt
database, only 15 spots were unambiguously identified for
both CD133low and CD133high cell populations (Table 1).
All the identified proteins were classified on the basis of
their main functional role. As shown in Table 2, the
majority of proteins that resulted down-modulated in
CD133high cells include cell cycle and apoptosis related
proteins and proteins involved in actin reorganization. In
CD133high cells, 3 proteins were up-regulated, namely the
actin-binding protein Tropomyosin 4 (Tm4), the regulator
of protein methylation Adenosylhomocysteinase (AdoH-
cyase) and the Eukaryotic translation initiation factor 3
subunit 2 (eIF3β) (Table 2). The validation of proteomic
results was performed by Western blot analysis of whole
lysates from CD133low and CD133high cells with antibodies
commercially available and of proven specificity directed
against some differentially expressed proteins. In particu-
lar, the higher amount of Tm4, eIF3β and AdoHcyase and
the lower amount of 14-3-3ε in CD133high in comparison
with CD133low cells was confirmed (Figure 3).PLC-β2 promotes the CD133high to CD133low conversion
To assess if the difference in malignancy-related features
between CD133low and CD133high cells may depend to
different expression/activation levels of proteins thought
to play a role in proliferation and invasiveness of breast
tumor cells, a Western blot analysis with specific anti-
bodies was performed. We focused on Akt, PLC-γ1 and133high cells unambiguously identified after
metry
Swiss Prot. Ac. n° Score Coverage (%) Peptides MWt Err ppm
P67936 651 33 10 29 6
P62258 116 22 2 29 7
P31947 103 13 2 28 9
P31946 433 35 9 28 8
P17987 573 23 9 61 11
P30740 547 38 10 43 8
P23526 453 19 9 48 7
P05198 196 13 4 36 5
P62714 125 22 2 36 4
Q13347 227 29 3 37 8
O94760 274 34 4 31.4 4
Q15181 281 30 6 33 8
P12429 549 34 10 36.5 4
P47756 351 30 6 31.6 7
P61289 122 11 3 30 3
Table 2 Biological functions and roles in breast cancer of proteins differentially expressed in CD133low and CD133high
cells
Proteins Main function/Biological process Known roles in breast cancer CD133high versus CD133low
Tm4 Actin-binding protein/Cell motility Metastasis (32), Chemotherapy resistance (34) Up
14-3-3 ε Protein binding/Cell cycle Chemotherapy resistance (34) Down
14-3-3 σ Protein binding/Cell cycle, apoptosis Tumor suppression (35) Down
14-3-3 β/α Protein binding/Cell cycle, apoptosis Chemotherapy resistance (34) Down
TCP-1-α Molecular chaperone/Cell motility Metastasis (36) Down
LEI Protease inhibitor/Protein metabolism Cell migration and invasiveness suppression (37) Down
AdoHcyase Hydrolase/Protein metabolism Oncogenic (38) Up
eIF-2A Initiation factor/Protein metabolism Protein biosynthesis (39) Down
PP2A- β Protein phosphatase/Apoptosis Tumor suppression (40) Down
eIF3β Initiation factor/Protein metabolism Oncogenic (41) Up
DDAH-1 Hydrolase/Metabolic pathways Unknown Down
PPase Pyrophosphate hydrolysis/Metabolic pathways Chemotherapy resistance (34) Down
Annexin A3 Phospholipase A2 inhibitor/Metabolic pathways Chemotherapy resistance (34) Down
CapZ β Actin capping/Cell motility Chemotherapy resistance (34) Down
PA28γ Protein binding/Cell cycle, apoptosis Unknown Down
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breast cancer progression, distant metastasis and poor out-
come, respectively [18-21]. As shown in Figure 4A, by
comparing total lysates from CD133low and CD133high







Figure 3 Protein profiles of CD133low and CD133high sub-
populations. Total lysates from CD133low and CD133high cells were
subjected to immunochemical analysis with the indicated antibodies.
Tubulin was blotted as a control for the equivalence of loaded protein.
The data are representative of three separate experiments.phosphorylation of Akt was found. Similarly, PLC-γ1 was
expressed at the same level and phosphorylated to the
same extent in the two
cellular subsets, while the amount of PLC-β2 in CD133low
cells was found remarkably higher than in CD133high cells
(Figure 4B).
To elucidate whether PLC-β2 may contribute to the dif-
ferent features of cells expressing different CD133 levels,
an EGFP-tagged human protein was over-expressed in
both CD133low and CD133high cells (Figure 5A). As shown
in Figure 5B, the forced expression of PLC-β2 was unable
to modify the invasive properties of CD133low cells but
induced a significant decrease of invasive potential of
CD133high cells. The co-expression of EGFP with PLC-β2
allowed to selectively monitor CD133 in transfected cells,
revealing that CD133high cells in which PLC-β2 resulted
over-expressed showed a significant reduction of CD133
levels, both at membrane (Figure 5C) and intracellular
(Figure 5D).
Experiments in which PLC-β2 expression in CD133low
cells was inhibited with specific siRNAs (Figure 6A) failed
to show any modification of CD133 levels (Figure 6B) but
evidenced a significant reduction of invasion capability
(Figure 6C).
Down modulation experiments with siRNAs specific for
CD133 (Figure 7A) demonstrated that this protein may be
involved in determining the high invasive potential of
CD133high cells, as shown by the significant decrease of
the invasion capability of CD133-silenced cells (Figure 7B).
Remarkably, among the proteins differentially expressed in
CD133low and CD133high cells, the silencing of CD133









Figure 4 Signalling molecules in CD133low and CD133high cells.
(A) Immunochemical analysis with the indicated antibodies of total
lysates from CD133low and CD133high cells. Tubulin was blotted as a
control for the equivalence of loaded protein. (B) Western blot analysis
of PLC-β2 of immunoprecipitates with an anti-PLC-β2 antibody from
CD133low and CD133high cells. Lysates from the same cells were
analyzed for β-tubulin content, as internal control of processed
proteins. The data are representative of three separate experiments.
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correlated with the ability to metastasize of breast
tumors [22].
The results indicating that, in triple negative breast
tumor cells expressing CD133, the up-regulation of
PLC-β2 levels reduces both CD133 expression and inva-
sion capability were confirmed in MDA-MB-468 cells
(Figure 8A). In this cell line, in which almost the entire
population expresses CD133, the over-expression of
PLC-β2, nearly absent in control cells (Figure 8B), sig-
nificantly reduces CD133 levels (Figure 8C) and the in-
vasion capability (Figure 8D).Discussion
Initially considered a marker of hematopoietic stem cells,
CD133/prominin is a glycosylated trans-membrane pro-
tein expressed in various solid tumors, including breastcancer, in which CD133-positivity seems to identify a re-
stricted subgroup of tumor progenitors [23,24]. In normal
mammary tissue, CD133/prominin is not a marker for
stem cells and seems to regulate ductal branching [25]. Be-
yond its possible relationship with stemness of tumor
cells, CD133 expression in breast cancer significantly cor-
relates with tumor stage, tumor size and occurrence of
lymph node metastases [26]. CD133 is also useful in pre-
dicting chemosensitivity to neoadjuvant chemotherapy in
breast cancer [27], suggesting that CD133 expression may
be of help in more accurately predicting the aggressive
properties and in determining the optimal therapeutic
strategy for this neoplasia. A strong correlation of CD133
expression with clinical stage of breast tumor patients was
observed in TNBC (ER-, PR- HER2-), a high risk breast
neoplasia that lacks the benefit of specific therapy that tar-
gets these receptors [3]. It has been recently demonstrated
that the expression of CD133 is associated with markers
of hypoxia and/or tumor microvasculature in human
breast tumors [12,28] and, in TNBC, CD133(+) cells with
cancer stem cell characteristics associate with vasculogenic
mimicry [29]. These data suggest that the tumor micro-
environment, and in particular hypoxia, induces in breast
cancer cells a basal-like phenotype that includes increased
expression of CD133 and decreased expression of hor-
mone receptors.
CD133 is expressed at the surface of several cancer
cells, not only with characteristics of stemness [30], but
a direct function of CD133 in determining specific fea-
tures of tumor cells was not described. In particular,
nothing is known about the role of CD133 in determin-
ing the biological properties of TNBC cells. This issue
was tentatively addressed with the highly tumorigenic
and moderately metastatic MDA-MB-231 cells [31],
which show an ER-, PR-, Her2- immunoprofile, mimick-
ing the condition that is characterized by a low response
to chemotherapy and worst prognosis in breast tumor
patients [32]. Here we show that the cytofluorimetrical
analysis with anti CD133 antibodies identifies, in the
bulk of the cell population, a low basal CD133 expression,
and in a small percentage of cells (2-3%), a much higher
expression level, making this cell line useful to compare
TNBC cells with different levels of CD133 expression.
By using antibodies directed against different CD133 epi-
topes [33,34] and Tunicamycin we ruled out the potential
bias arising from variable glycosylation levels and from
glycosylation-dependent epitopes in the extracellular por-
tion of CD133 that it was reported to be potentially lost
upon differentiation of tumor cells [5]. We also extended
the analysis to intracellular CD133 that allowed to defin-
itely confirm the existence, in MDA-MB-231 cells, of a
small but stable subpopulation expressing high levels of
CD133 in both membrane and cytoplasm compartments.
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Figure 5 PLC-β2 and CD133 expression. (A) Western blot analysis with the indicated antibodies of CD133low and CD133high cells transfected with a
construct expressing EGFP-tagged human PLC-β2 (EGFP-PLC-β2). (B) Dynamic monitoring of invasion through Matrigel using the xCELLigence system of
transfected cells. (C) Cytofluorimetrical analysis of surface expression of CD133 by direct staining with PE-conjugated 293C3 antibody. (D) Cytofluorimetrical
analysis of intracellular CD133 with PE-conjugated 293C3 antibody of transfected CD133high cells. Only EGFP-expressing cells were analyzed. The asterisks
indicate statistically significant differences (P< 0.05). Error bars indicate ± SD. All the data are representative of three separate experiments.
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proliferation and migration rate together with a larger ad-
hesion area, consistent with a more undifferentiated tu-
moral phenotype. Interestingly, CD133high cells exhibit a
higher invasion capability through Matrigel, suggestive of
higher metastatic potential. This is consistent with the
data obtained in triple negative tumors, in which CD133
expression levels positively correlate with metastatization
to lymph nodes [3].
Protein profiles of CD133low and CD133high cells were
compared by means of 2D analysis followed by mass
spectrometry, showing that a number of proteins already
known to be de-regulated in breast cancer [22,35-42] are
differentially expressed between the two sub-populations.
In particular, CD133low cells that proliferate and migrate
faster than CD133high cells, show higher expression of pro-
teins regulating cell motility. Interestingly, CD133high cells,
which exhibit a more invasive phenotype, show higherexpression of the actin-binding protein Tm4, that was re-
ported to be up-regulated in highly metastatic breast can-
cer cell lines and to be associated with the presence of
lymph node metastasis of breast tumors [22]. Tms are a
family of cytoskeletal proteins present in virtually all
eukaryotic cells, where they bind actin filaments and
stabilize their structure [43]. Changes in the expression of
specific Tms are commonly found in malignantly trans-
formed cells and overexpression of Tm4 in breast cancer
cells is related to metastatic behaviour and may be a useful
marker for predicting distant metastasis [32]. In compari-
son to CD133low cells, CD133high cells also express higher
levels of AdoHcyase, known to play a key role in the con-
trol of methylation [44] and that, in breast cancer, seems
to be involved in regulation of histone methylation via the
2 member enhancer of zeste homolog 2 (EZH2) [39].
Since inhibition of AdoHcyase results in G2/M cell cycle























Figure 6 PLC-β2 and invasiveness of CD133low cells. (A) Immunochemical analysis of immunoprecipitates with the anti-PLC-β2 antibody from
CD133low cells transfected with siRNAs specific for PLC-β2 (PLC-β2 siRNAs). A non-silencing scramble siRNAs was used as a control (ctrl siRNAs).
Lysates from the same cells were analyzed for β-tubulin content, as internal control of processed proteins. (B) Cytofluorimetrical analysis of surface
expression of CD133 by direct staining with PE-conjugated 293C3 antibody and (C) dynamic monitoring of invasion through Matrigel using the
xCELLigence system of transfected cells. Error bars indicate ± SD. All the data are representative of three separate experiments.
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enzyme might be of therapeutic value in breast cancer.
Also the expression levels of a member of the eukaryotic
initiation factor eIF3 family is higher in CD133high than in
CD133low cells. eIF3 complex is essential for initiation of
protein synthesis and the β subunit was already reported to
be over-expressed in human breast carcinoma [42]. Data
on glioblastoma cells suggested for eIF3β an oncogenic role
since its down-modulation inhibited cell proliferation and
increased the apoptosis rate [45]. This evidence indicates
that, at least in TNBC cells, high expression of CD133
identifies cells with a peculiar protein expression pattern
which accounts for their relatively differentiated tumoral
phenotype together with high metastatic potential. Con-
cerning the signalling molecules known to modulate prolif-
eration/motility of breast tumor cells, no differences have
been observed between CD133high and CD133low cells inthe expression and activation levels of Akt, whose activity
seems to have dichotomous effects on neoplastic progres-
sion of breast cancer [19]. Also expression and activation
levels of PLC-γ1, correlated with distant metastases of early
breast tumors [21] and involved in metastatic properties of
TNBC cells [46] were investigated. However, no difference
between the two sub-populations expressing different
levels of CD133 was found. On the contrary, CD133high
cells express PLC-β2 at levels significantly lower than
CD133low cells, in accordance with our previous data indi-
cating that, in breast tumor-derived cells, PLC-β2 amount
positively correlates with proliferation rate and motility
[16]. In particular, our previous studies on MDA-MB-231
cells, 98% of which express basal levels of CD133, have
demonstrated that the down-modulation or the over-
expression of PLC-β2 respectively reduces or increases




























Figure 7 CD133 and invasiveness of CD133high cells. (A) Western blot analysis with the anti-CD133 antibody of mmunoprecipitates with anti-
CD133 antibody from CD133high cells transfected with specific siRNAs (CD133 siRNAs). A non-silencing scramble siRNAs was used as a control (ctrl
siRNAs). Lysates from the same cells were analyzed for β-tubulin content, as internal control of processed proteins. (B) Dynamic monitoring of
invasion through Matrigel using the xCELLigence system of transfected cells. Error bars indicate ± SD. (C) Immunochemical analysis with the
indicated antibodies of lysates from CD133high cells in which CD133 expression was down-modulated. Tubulin was blotted as a loading control.
The data are representative of three separate experiments.
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decreases invasion capability of MDA-MB-231 but its over-
expression fails to affect their invasion capability through
Matrigel [16], indicating that the sole PLC-β2 is necessary
but not sufficient to sustain the metastatic potential of
TNBC cells. Here we show a peculiar role of PLC-β2 in
cells expressing high levels of CD133. In fact, the over-
expression of PLC-β2 in CD133high cells, which contain
relatively low levels of the protein, is able to induce a sig-
nificant decrease of their invasion capability, in parallel
with a reduced expression of CD133, at both membraneand cytoplasm levels. When the expression of PLC-β2
was down-modulated in CD133low cells, containing rela-
tively high levels of the protein if compared with CD133high
cells, a significant decrease of invasion capability was
observed, according with our data previously obtained on
the entire MDA-MB-231 cell population (accounting for
about 98% of CD133low cells) [16]. The lack of effects of
PLC-β2 down-modulation on CD133 expression in
CD133low cells confirms that the two sub-populations
expressing different CD133 levels correspond to different
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D
Figure 8 CD133 and PLC-β2 expression in MDA-MB-468 cells. (A) CD133 surface expression evaluated in MDA-MB-468 cells by means of flow
cytometry after staining with PE-conjugated 293C3 antibody and presented on a biparametric dot plot. The quadrants are gated to separate positive
populations. The percentage of cells expressing high levels of CD133 is indicated at the upper right of each panel, together with their mean fluorescence
intensity (MFI). (B) Western blot analysis with the indicated antibodies of MDA-MB-468 cells transfected with a construct expressing EGFP-tagged human
PLC-β2 (EGFP-PLC-β2). (C) Cytofluorimetrical analysis of surface expression of CD133 by direct staining with PE-conjugated 293C3 antibody of transfected
cells. Only EGFP-expressing cells were analyzed. The asterisk indicates statistically significant differences (P< 0.05). (D) Dynamic monitoring of invasion
through Matrigel using the xCELLigence system of transfected cells. Error bars indicate ± SD. All the data are representative of three separate experiments.
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http://www.molecular-cancer.com/content/12/1/165signalling mechanisms take place. In this context, while
PLC-β2 promotes the conversion of CD133high to
CD133low cells, its silencing in cells showing a more differ-
entiated tumoral phenotype (CD133low) is not sufficient to
revert the phenomenon.
A reduction of invasiveness trough Matrigel of CD133high
cells was found also when CD133 expression was forcedly
down-modulated by specific siRNAs, indicating that CD133
is primarily involved in invasion capability of TNBC-derived
cells. The mechanism may be correlated with the preferen-
tial localization of CD133 in plasma membrane protrusions,
ended to regulate lipid composition and membrane top-
ology [4]. By establishing and maintaining membrane pro-
trusions, CD133 may be involved in cell polarity and
migration and may regulate the invasive properties of
TNBC cells. On the other hand, the decreased expression
of Tm4 observed after down-modulation of CD133 in
highly expressing cells allows to speculate on a more spe-
cific mechanism by which CD133 can promote invasiveness
of tumor cells, taking into account that the expression of
specific isoforms of the Tms family correlates with the
metastatic potential of TNBC-derived cells [22].
The results indicating that up-regulation of PLC-β2 in
cells expressing high levels of CD133 reduces the expres-
sion of this glysosylated protein in parallel with the invasion
capability of CD133high cells was confirmed in MDA-MB-
468, a triple negative cell line expressing CD133 at high
levels [47] and almost negative for PLC-β2. The overall re-
sults indicate that, in TNBC cells, the increased expression
of PLC-β2 down-regulates invasiveness only in cells with
high levels of CD133 since this PLC isozyme negatively
modulates the expression of CD133, in turn involved in de-
termining the invasive properties of CD133high cells.Conclusions
The high expression of CD133 in TNBC-derived cells
correlates with high invasive potential and with a pecu-
liar pattern of protein expression that includes the up-
regulation of molecules correlated with lymph node me-
tastasis of breast tumors. The aggressive properties of
CD133high cell are mitigated by PLC-β2 which, despite
its general role in sustaining motility of breast tumor
cells, down-modulates the expression of CD133 and thus
may play a role in preventing metastatic progression of
CD133 positive TNBC.
Considering that the relevance of CD133 in malig-
nancy of breast tumors is well established, our finding
that PLC-β2 is involved in CD133-mediated invasiveness
of cells derived from TNBC can contribute to better
estimate the prognosis and more accurately identify
therapeutic targets for TNBC, which remains a highly
heterogeneous type of cancer and often an incurable
illness.Materials and methods
Cell culture and reagents
All reagents were from Sigma (St Louis, Mo., USA) un-
less otherwise indicated.
The breast cancer-derived cell line MDA-MB-231 and
MDA-MB-468 and the human colon cancer cell line Caco-
2 were purchased from the American Type Culture Collec-
tion (Rockville, MD). MDA-MB-231 and MDA-MB-468
cells were grown in high-glucose Dulbecco's modified
Eagle's medium (DMEM, Gibco Laboratories, Grand Is-
land, NY) supplemented with 10% fetal bovine serum
(FBS, Gibco Laboratories). Caco-2 cells were cultured in
DMEM with 1% Non-essential Amino Acid (NEAA, Lonza
Sales Ltd, Basel, CH), 1% Sodium Pyruvate (Gibco Labora-
tories), 1% Penicillin-streptomycin solution (Lonza) and
10% FBS. All cell lines were grown at 37°C in a humidified
atmosphere of 5% CO2 in air.
To inhibit N-glycosylation, Caco-2 and MDA-MB-231
cells were cultured in the presence of 2.5 μg/ml Tunica-
mycin or vehicle (medium containing 0.1% DMSO) for
24 hours.
Evaluation of CD133 expression
CD133 surface expression was evaluated by means of
flow cytometry by direct staining of the cells with
phycoerythrin (PE)-conjugated anti-CD133/1 (AC133)
and anti-CD133/2 (293C3) mouse monoclonal anti-
bodies (Miltenyi Biotec, Bologna, I), as suggested by
manufacter's protocol, and by indirect labelling with a
hybridoma supernatant (clone 7) containing a monoclo-
nal antibody directed against unmodified CD133 epi-
topes, kindly provided by Dr. Panyam and Ohlfest
(University of Minnesota) and used as described by
Swaminathan et al. [33]. In particular, 5×105 cells were
stained with 100 μl of clone 7 hybridoma supernatant
and reacted with a secondary anti-mouse-PE antibody
(Becton-Dickinson, San José, CA).
For analysis of intracellular amounts of CD133, Perm
and Stab Solutions Kit (Instrumentation Laboratory S.p.
A, Milan, I) was used, performing the staining with anti-
CD133/2-PE antibody, as suggested by manufacturers.
All the samples were analyzed by a FACSCalibur flow
cytometer (Becton-Dickinson) with CellQuest Pro 6.0
software (Becton-Dickinson). Data collected from 10 000
cells are shown as percentage of positive cells or as
mean fluorescence intensity (MFI) values.
Immunomagnetic separation
MDA-MB-231 cells were resuspended in PBS containing
0.5% bovine serum albumin and 2 mmol/L EDTA. For
magnetic labeling, CD133/1 Micro Beads were used
(Miltenyi Biotech) and positive magnetic cell separation
was done using MACS SD columns (Miltenyi Biotech),
according to manufacturer's instructions. CD133low and
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above reported medium and subjected to morphological
analysis, to xCELLigence RTCA assays and to modula-
tion of PLC-β2 and CD133 expression.
Two-dimensional gel electrophoresis and mass
spectrometry
2-DE was performed essentially as described by Bertag-
nolo et al. [48], with some modifications. Briefly, CD133low
and CD133 high cells were lysed with 2 M thiourea, 7 M
urea, 4% CHAPS, 1% DTT, 2% IPG buffer pH 3–10 (Bio-
Rad, Hercules, CA), benzonase and protease inhibitors,
followed by heating for 30 min at 30°C, sonication and
centrifugation at 21 000 × g for 60 min at 4°C. Supernatant
containing 400 μg of proteins was used to rehydrate 17 cm
pH 4–7 IPG gel strips (Bio-Rad) for 16 h at 20°C. Focusing
was carried out on PROTEAN IEF cell (Bio-Rad) using
the following conditions: 250 V (60 min), 500 V (60 min),
1000 V (60 min), 5000 V (60 min), 10 000 V (60 min) and
10 000 V for the additional time required to reach a total
of 80 kVh. The separation in the second dimension was
performed using 1 mm thick, 12% constant vertical SDS-
PAGE in PROTEAN II xi apparatus (Bio-Rad) at constant
35 mA/gel. The gels were stained with Coomassie Brilliant
Blue G-250 (Bio-Rad) and scanned using a Pharos-FX
Molecular Imager (Bio-Rad). The acquired maps were an-
alyzed using the PDQuest Basic Version 8.0 software (Bio-
Rad), as previously reported [48]. A difference in intensity
of 200% between spots of two compared gels was consid-
ered significant. Spots of interest were excised using a ster-
ile blade and subjected to mass spectrometry analysis
essentially as described by Bavelloni et al. [49]. For peptide
sequence searching, monoisotopic peptide mass lists were
submitted to Mascot v.2.1 (Matrix Science, London, UK)
against the UniProtKB-SwissProt database (April 23, 2012,
total of 535 698 entries). The search parameters were as
follows: two missed cleavage allowed, carbamidomethyla-
tion of cysteine as fixed modification, oxidation of methio-
nines as variable modification, precursor ion mass
tolerance 50 ppm and fragment ion tolerance 1 Da.
Analysis of adhesion area
The morphology of CD133low and CD133high MDA-MB-
231 cells was analyzed with an inverted phase-contrast
microscope (Nikon Eclipse TE2000-E; Nikon, Florence, I)
and cell images were acquired by the ACT-1 software with
a DXM1200F digital camera (Nikon) and analyzed with
the ImageJ software, as previously reported [50].
Real-time cell proliferation, migration and invasion assays
Cell proliferation, migration and invasiveness were evalu-
ated by means of the xCELLigence RTCA System (Real-
Time Cell Analyzer System, Roche Applied Science,
Mannheim, D), developed to monitor cell events in realtime by measuring the electrical impedance produced by
cells. The employed procedures were essentially those de-
scribed by Stander et al. [51] for proliferation kinetics and
by Mandel et al. [52] for migration and invasiveness assays.
In particular, to measure cell proliferation, 5000 cells ⁄well
were used with a programmed signal detection every
15 min for a total of 96 h. For migration assays, 4 ×
104 cells∕well were seeded onto the top chambers of CIM-
16 plates (Roche) and the bottom chambers were filled
with medium containing 5% serum. The setup for analysis
of invasiveness was the same described for migration ex-
cept that the upper side of the membranes was covered
with a layer of Matrigel (BD Biosciences, San Josè, CA)
diluted 1:20 and the bottom chambers were filled with
10% serum containing medium. For both migration and
invasion assays, the signal detection was programmed
every 15 min for a total of 24 h. Impedance values were
expressed as a dimensionless parameter (cell index, CI).
Modulation of PLC-β2 and CD133 expression
PLC-β2 over-expression was performed by transient trans-
fection with a plasmid expressing an Enhanced Green
Fluorescent Protein (EGFP)-tagged full-length human
PLC-β2, as previously reported [16].
The down-modulation of CD133 and of PLC-β2 was
performed by silencing the proteins with specific siRNAs
(Santa Cruz Biotechnology, Santa Cruz, CA), following a
previously described procedure [16]. As a control of trans-
fection efficiency a non-silencing fluorescein-labeled du-
plex RNA, purchased from Qiagen (Milan, I), was used.
The transfected cells were incubated at 37°C in a 5% CO2
atmosphere for 48 h and then subjected to immunochemi-
cal and cytofluorimetrical analysis and to xCELLigence
RTCA assays.
Immunoprecipitation and immunochemical analysis
PLC-β2 was immunoprecipitated from CD133low and
CD133high MDA-MB-231 cells and CD133 was immuno-
precipitated with an anti-CD133/1 (W6B3C1, Miltenyi)
from MDA-MB-231, CD133high MDA-MB-231 and Caco-
2 cells following a previously reported procedure [16].
Total lysates and immunoprecipitates were separated on
7.5% polyacrylamide denaturing gels and blotted to nitro-
cellulose membranes (GE Healthcare Life Science, Little
Chalfont, UK). The membranes were then incubated with
antibodies directed against pY783-PLCγ1, PLC-γ1, PLC-
β2, 14-3-3ε, eIF3β, AdoHcyase and Akt (Santa Cruz Bio-
technology), pS473-Akt and Tm4 (Millipore S.p.A., Milan,
I), CD133/1 (W6B3C1, Miltenyi Biotec) and β-tubulin
(Sigma). The chemiluminescence derived bands were ac-
quired with ImageQuant™ LAS 4000 biomolecular imager
(GE Healthcare) and the densitometric analysis was
performed by means of Image Quant TL software (GE
Healthcare).
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The results were expressed as means ± standard deviations
of three independent experiments. Statistical analysis was
performed by using the two-tailed Student's t-test for un-
paired data. P values ≤0.05 were considered statistically
significant.
Additional file
Additional file 1: Figure S1. Total lysates from Caco-2 and MDA-MB-
231 cells, cultured in the presence of 2.5 μg/ml Tunicamycin or vehicle
(DMSO) for 24 hours, were immunoprecipitated with the W6B3C1
anti-CD133 antibody and subjected to Western blot analysis. The data
are representative of two separate experiments performed in duplicate.
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